Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 4
2004 9
2005 2
2006 3
2007 7
2008 3
2009 1
2010 4
2015 3
2016 2
2018 1
2019 1
2020 5
2021 5
2022 1
2023 5
2024 5
2025 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

60 results

Results by year

Filters applied: . Clear all
Page 1
Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults.
Foà R, Bassan R, Vitale A, Elia L, Piciocchi A, Puzzolo MC, Canichella M, Viero P, Ferrara F, Lunghi M, Fabbiano F, Bonifacio M, Fracchiolla N, Di Bartolomeo P, Mancino A, De Propris MS, Vignetti M, Guarini A, Rambaldi A, Chiaretti S; GIMEMA Investigators. Foà R, et al. N Engl J Med. 2020 Oct 22;383(17):1613-1623. doi: 10.1056/NEJMoa2016272. N Engl J Med. 2020. PMID: 33085860 Clinical Trial.
Novel insights and therapeutic approaches in secondary AML.
Marconi G, Rondoni M, Zannetti BA, Zacheo I, Nappi D, Mattei A, Rocchi S, Lanza F. Marconi G, et al. Among authors: rondoni m. Front Oncol. 2024 Jul 29;14:1400461. doi: 10.3389/fonc.2024.1400461. eCollection 2024. Front Oncol. 2024. PMID: 39135995 Free PMC article. Review.
Long-term real-world evidence of CPX-351 of high-risk patients with AML identified high rate of negative MRD and prolonged OS.
Cluzeau T, Guolo F, Chiche E, Minetto P, Rahme R, Bertoli S, Fianchi L, Micol JB, Gottardi M, Peterlin P, Galimberti S, Thomas X, Rizzuto G, Legrand O, Rondoni M, Raffoux E, Bertani G, Caulier A, D'Argenio M, Bonmati C, Billio A, Lejeune C, Scappini B, Pigneux A, Zappasodi P, Recher C, Grimaldi F, Ades L, Lemoli RM. Cluzeau T, et al. Among authors: rondoni m. Blood Adv. 2025 Feb 25;9(4):752-758. doi: 10.1182/bloodadvances.2024014279. Blood Adv. 2025. PMID: 39454204 Free PMC article.
Identification of Novel Potential Predisposing Variants in Familial Acute Myeloid Leukemia.
Ronchini C, Gigli F, Fontanini M, Furgi R, Amato V, Giglio F, Gregato G, Bertolini F, Rondoni M, Lanza F, Billio A, Derenzini E, Tarella C, Pelicci PG, Alcalay M, Todisco E. Ronchini C, et al. Among authors: rondoni m. Cancer Rep (Hoboken). 2024 Aug;7(8):e2141. doi: 10.1002/cnr2.2141. Cancer Rep (Hoboken). 2024. PMID: 39118233 Free PMC article.
Multicenter Observational Retrospective Study on Febrile Events in Patients with Acute Myeloid Leukemia Treated with Cpx-351 in "Real-Life": The SEIFEM Experience.
Fianchi L, Guolo F, Marchesi F, Cattaneo C, Gottardi M, Restuccia F, Candoni A, Ortu La Barbera E, Fazzi R, Pasciolla C, Finizio O, Fracchiolla N, Delia M, Lessi F, Dargenio M, Bonuomo V, Del Principe MI, Zappasodi P, Picardi M, Basilico C, Piedimonte M, Minetto P, Giordano A, Chiusolo P, Prezioso L, Buquicchio C, Melillo LMA, Zama D, Farina F, Mancini V, Terrenato I, Rondoni M, Urbino I, Tumbarello M, Busca A, Pagano L. Fianchi L, et al. Among authors: rondoni m. Cancers (Basel). 2023 Jul 1;15(13):3457. doi: 10.3390/cancers15133457. Cancers (Basel). 2023. PMID: 37444567 Free PMC article.
Rearrangements of ATP5L-KMT2A in acute lymphoblastic leukaemia.
Ferrari A, Ghelli Luserna Di Rora A, Domizio C, Papayannidis C, Simonetti G, Maria Hernández-Rivas J, Rondoni M, Giglio F, Abruzzese E, Imovilli A, Iacobucci I, Calistri D, Martinelli G. Ferrari A, et al. Among authors: rondoni m. Br J Haematol. 2021 Mar;192(6):e139-e144. doi: 10.1111/bjh.17265. Epub 2020 Dec 13. Br J Haematol. 2021. PMID: 33314053 Clinical Trial. No abstract available.
Impact of Pre-Treatment Comorbidity Burden on Survival in Patients Receiving Venetoclax Plus Hypomethylating Agents.
Marconi G, Petracci E, Lanzarone G, Vetro C, Martelli MP, Papayannidis C, Audisio E, Minetto P, Riva C, Guolo F, Martini G, Zappasodi P, Vincenzo F, Gigli F, Griguolo D, Rondoni M, Ciotti G, Borlenghi E, Ciccone N, Palumbo FE, Nanni J, Mattei D, Bernardi M, Cignetti A, Zingaretti C, Vertogen B, Cerchione C, Lanza F, Cilloni D, Brunetti L, Palmieri R, Curti A, Giannini MB, Todisco E; AVALON research group; Fracchiolla N, Martinelli G. Marconi G, et al. Among authors: rondoni m. Am J Hematol. 2025 Apr;100(4):708-711. doi: 10.1002/ajh.27591. Epub 2025 Jan 20. Am J Hematol. 2025. PMID: 39831709 Free PMC article.
Comparison between indolent systemic mastocytosis and clonal mast cell disease not meeting WHO diagnostic criteria: A nationwide multicenter retrospective analysis.
Sciumè M, Serpenti F, Zanotti R, Bonadonna P, Tanasi I, Crosera L, Elena C, Mannelli F, Crupi F, Papayannidis C, Sartor C, Soverini S, Rondoni M, Eller-Vainicher C, Pravettoni V, Rivolta F, Alberti Violetti S, Croci GA, Migliorini AC, Bolli N, Giannarelli D, Grifoni FI. Sciumè M, et al. Among authors: rondoni m. Hematol Oncol. 2024 May;42(3):e3277. doi: 10.1002/hon.3277. Hematol Oncol. 2024. PMID: 38682493 No abstract available.
60 results